Skip to content

ENDONOVO THERAPEUTICS, INC.: 10-Q filed 2020-11-19

What ENDONOVO THERAPEUTICS, INC. reported in its quarterly report filed 2020-11-19 (fiscal Q3 2020): 42 published measures, 115 facts as tagged in accession 0001493152-20-022038.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-19
Fiscal period
fiscal Q3 2020
Accession
0001493152-20-022038 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ENDONOVO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-302,732,104USD
At 2019-12-313,274,650USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-3015,494,386USD
At 2019-12-3123,778,470USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-12,762,282USD
At 2020-06-30-12,182,520USD
At 2020-03-31-11,141,852USD
At 2019-12-31-20,503,820USD
At 2019-09-30-16,565,996USD
At 2019-06-30-16,246,895USD
At 2019-03-31-11,624,678USD
At 2018-12-31-11,391,838USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-302,583USD
At 2019-12-3118,893USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,069,041USD92
2020-01-01 to 2020-09-301,634,726USD274
2020-04-01 to 2020-06-30-1,634,651USD91
2020-01-01 to 2020-03-314,338,418USD91
2019-07-01 to 2019-09-30-1,406,196USD92
2019-01-01 to 2019-09-30-11,649,967USD273
2019-04-01 to 2019-06-30-7,837,546USD91
2019-01-01 to 2019-03-31-2,406,225USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-548,734USD274
2019-01-01 to 2019-09-30-2,232,626USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-09-302,594USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-07-01 to 2020-09-3039,980USD92
2020-01-01 to 2020-09-30154,296USD274
2019-07-01 to 2019-09-3054,039USD92
2019-01-01 to 2019-09-30161,720USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-30532,424USD274
2019-01-01 to 2019-09-301,861,106USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2019-01-01 to 2019-09-30-2,594USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-51,308,212USD
At 2019-12-31-52,934,786USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-07-01 to 2020-09-3016,137,373shares92
2020-01-01 to 2020-09-309,621,530shares274
2019-07-01 to 2019-09-30777,249shares92
2019-01-01 to 2019-09-30613,272shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-07-01 to 2020-09-3016,137,373shares92
2020-01-01 to 2020-09-3023,575,380shares274
2019-07-01 to 2019-09-30777,249shares92
2019-01-01 to 2019-09-30613,272shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-0.07USD/shares92
2020-01-01 to 2020-09-300.17USD/shares274
2019-07-01 to 2019-09-30-1.81USD/shares92
2019-01-01 to 2019-09-30-19USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-0.07USD/shares92
2020-01-01 to 2020-09-30-0.15USD/shares274
2019-07-01 to 2019-09-30-1.81USD/shares92
2019-01-01 to 2019-09-30-19USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-302,483USD
At 2019-12-315,915USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-30400,108USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-946,799USD92
2020-01-01 to 2020-09-30-2,228,237USD274
2019-07-01 to 2019-09-30-1,291,263USD92
2019-01-01 to 2019-09-30-3,079,075USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-308,625USD
At 2019-12-3162,555USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-3015,339,386USD
At 2019-12-3123,623,470USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-09-30762,175USD
At 2019-12-31599,470USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2020-09-302,720,996USD
At 2019-12-313,206,180USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-09-30942USD
At 2019-12-3122,742USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-30986,019USD92
2020-01-01 to 2020-09-302,364,213USD274
2019-07-01 to 2019-09-301,336,377USD92
2019-01-01 to 2019-09-303,194,586USD273

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-3039,220USD92
2020-01-01 to 2020-09-30135,976USD274
2019-07-01 to 2019-09-3045,114USD92
2019-01-01 to 2019-09-30115,511USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-07-01 to 2020-09-30760USD92
2020-01-01 to 2020-09-3018,320USD274
2019-07-01 to 2019-09-308,925USD92
2019-01-01 to 2019-09-3046,209USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-300USD92
2020-01-01 to 2020-09-303,283USD274
2019-07-01 to 2019-09-3034,708USD92
2019-01-01 to 2019-09-3088,022USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-3017,303,952shares
At 2019-12-311,189,204shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3038,545,743USD
At 2019-12-3132,432,392USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2020-09-306,217,354USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-09-3089,794USD
At 2019-12-3189,794USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-09-3087,311USD
At 2019-12-3183,879USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-302,600USD
At 2019-12-3120,920USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,069,041USD92
2020-01-01 to 2020-09-301,634,726USD274
2019-07-01 to 2019-09-30-1,406,196USD92
2019-01-01 to 2019-09-30-11,649,967USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-09-303,432USD274
2019-01-01 to 2019-09-302,501USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-09-30488,616USD274
2019-01-01 to 2019-09-30487,684USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2020-01-01 to 2020-09-30485,184USD274
2019-01-01 to 2019-09-30485,183USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-58,902USD92
2020-01-01 to 2020-09-30-58,902USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-122,242USD92
2020-01-01 to 2020-09-303,862,963USD274
2019-07-01 to 2019-09-30-114,933USD92
2019-01-01 to 2019-09-30-8,570,892USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-09-3015,300USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-21,800USD274
2019-01-01 to 2019-09-307,931USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-3082,006USD274
2019-01-01 to 2019-09-30188,792USD273

Inspect the source

Entity
ENDONOVO THERAPEUTICS, INC. / CIK 0001528172
Captured
2026-09-20T09:15:36.026Z
SEC response SHA-256
77af3f2eba134146bbd094e17b18f0fd658f8dd873b389b6434b1de9b2ac5f8a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001528172.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))